SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 274 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $92,000 | -96.5% | 2,991 | -97.1% | 0.00% | -95.5% |
| Q1 2021 | $2,655,000 | +4.4% | 101,411 | +0.3% | 0.04% | -6.4% |
| Q4 2020 | $2,543,000 | +20.8% | 101,077 | 0.0% | 0.05% | +2.2% |
| Q3 2020 | $2,106,000 | -21.2% | 101,077 | -10.2% | 0.05% | -25.8% |
| Q2 2020 | $2,672,000 | +32.0% | 112,497 | 0.0% | 0.06% | +12.7% |
| Q1 2020 | $2,024,000 | -24.2% | 112,497 | -0.1% | 0.06% | -1.8% |
| Q4 2019 | $2,671,000 | -15.0% | 112,600 | -1.5% | 0.06% | -8.2% |
| Q3 2019 | $3,141,000 | +24.1% | 114,300 | +49.4% | 0.06% | +15.1% |
| Q2 2019 | $2,531,000 | +9.6% | 76,500 | +16.1% | 0.05% | +8.2% |
| Q1 2019 | $2,309,000 | -58.1% | 65,900 | -50.0% | 0.05% | -23.4% |
| Q4 2018 | $5,507,000 | +66.0% | 131,800 | +100.0% | 0.06% | -11.1% |
| Q3 2018 | $3,318,000 | -15.5% | 65,900 | +0.5% | 0.07% | -16.3% |
| Q2 2018 | $3,926,000 | +30.7% | 65,600 | 0.0% | 0.09% | +24.6% |
| Q1 2018 | $3,004,000 | – | 65,600 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |